Liposomal eribulin for advanced adenoid cystic carcinoma, gastric cancer, esophageal cancer, and small cell lung cancer.
E7389-LF
advanced solid tumors
eribulin
granulocyte-colony stimulating factor
liposome
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
revised:
10
02
2022
received:
14
01
2022
accepted:
23
06
2022
pubmed:
23
7
2022
medline:
1
2
2023
entrez:
22
7
2022
Statut:
ppublish
Résumé
In this open-label, Phase 1 study, we explore the safety and efficacy of E7389-LF (liposomal formulation of eribulin) in Japanese patients with advanced solid tumors. This open-label, Phase 1 study enrolled Japanese adult patients to receive E7389-LF for the treatment of advanced solid tumors. Treatment with E7389-LF 2.0 mg/m As of October 16, 2020, 43 patients were enrolled (adenoid cystic carcinoma, n = 12; gastric cancer, n = 10; esophageal cancer, n = 11; small cell lung cancer, n = 10). Thirty-three patients experienced a Grade ≥3 treatment-related treatment-emergent adverse event, most commonly neutropenia (53.5%). Additionally, the incidence of hypersensitivity did not appear to change with a reduced number of infusion steps (2 vs. 4) and patients who were administered prophylactic pegylated granulocyte-colony stimulating factor had a noticeably lower incidence of Grade 3-4 neutropenia (although this did not have a proper control). The overall objective response rate was 11.6% (95% confidence interval: 3.9-25.1), corresponding to two partial responses in patients with adenoid cystic carcinoma, two partial responses in gastric cancer, and one partial response in esophageal cancer. Median progression-free survival was longer in the adenoid cystic carcinoma population (16.6 months) than in others. E7389-LF 2.0 mg/m
Sections du résumé
BACKGROUND
In this open-label, Phase 1 study, we explore the safety and efficacy of E7389-LF (liposomal formulation of eribulin) in Japanese patients with advanced solid tumors.
METHODS
This open-label, Phase 1 study enrolled Japanese adult patients to receive E7389-LF for the treatment of advanced solid tumors. Treatment with E7389-LF 2.0 mg/m
RESULTS
As of October 16, 2020, 43 patients were enrolled (adenoid cystic carcinoma, n = 12; gastric cancer, n = 10; esophageal cancer, n = 11; small cell lung cancer, n = 10). Thirty-three patients experienced a Grade ≥3 treatment-related treatment-emergent adverse event, most commonly neutropenia (53.5%). Additionally, the incidence of hypersensitivity did not appear to change with a reduced number of infusion steps (2 vs. 4) and patients who were administered prophylactic pegylated granulocyte-colony stimulating factor had a noticeably lower incidence of Grade 3-4 neutropenia (although this did not have a proper control). The overall objective response rate was 11.6% (95% confidence interval: 3.9-25.1), corresponding to two partial responses in patients with adenoid cystic carcinoma, two partial responses in gastric cancer, and one partial response in esophageal cancer. Median progression-free survival was longer in the adenoid cystic carcinoma population (16.6 months) than in others.
CONCLUSIONS
E7389-LF 2.0 mg/m
Identifiants
pubmed: 35864593
doi: 10.1002/cam4.4996
pmc: PMC9883537
doi:
Substances chimiques
eribulin
LR24G6354G
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1269-1278Informations de copyright
© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Support Care Cancer. 2020 Nov;28(11):5085-5097
pubmed: 32621264
Nanomaterials (Basel). 2020 Jan 22;10(2):
pubmed: 31978968
Lancet Oncol. 2018 Nov;19(11):1437-1448
pubmed: 30355453
Pharmaceutics. 2017 Mar 27;9(2):
pubmed: 28346375
Br J Cancer. 2019 Feb;120(4):379-386
pubmed: 30679780
Lancet. 2011 Mar 12;377(9769):914-23
pubmed: 21376385
J Clin Oncol. 2015 Oct 1;33(28):3199-212
pubmed: 26169616
Lancet. 2017 Dec 2;390(10111):2461-2471
pubmed: 28993052
Thorac Cancer. 2019 Apr;10(4):1005-1008
pubmed: 30859745
Cancer Med. 2023 Jan;12(2):1269-1278
pubmed: 35864593
Int J Pharm. 2013 Feb 25;443(1-2):9-16
pubmed: 23313921
BMC Cancer. 2020 Apr 28;20(1):358
pubmed: 32345249
J Clin Oncol. 2019 Jun 20;37(18):1529-1537
pubmed: 30939095
Head Neck. 2018 Mar;40(3):584-589
pubmed: 29283469